Purpose of review Treatment of aggressive pituitary tumours often yields suboptimal control of the tumour and confers significant morbidity. Lactotroph and corticotroph-derived tumours express ErbB receptors and ligands, and mutations in ubiquitin-specific protease 8 (USP8), which alters epidermal growth factor receptor (EGFR) degradation, have been implicated in Cushing disease pathogenesis. EGFR tyrosine kinase inhibitor (TKI) therapy has emerged as a potential new therapeutic approach for patients with aggressive prolactinomas and Cushing disease.
INTRODUCTION
Pituitary tumours are invariably benign, slow growing lesions, and regardless of whether they clinically secrete hormone can manifest aggressive behaviour and extensive growth and, rarely, metastasize [1] . Current treatment options for aggressive pituitary tumours are insufficient to control tumour growth and often confer significant morbidity. Therapeutic targeting of molecular pathway shown to be involved in pituitary tumorigenesis may offer alternative treatments for these patients. One potential target is the epidermal growth factor receptor (EGFR) pathway. EGFR belongs to the ErbB family of membrane receptor kinases, including EGFR [also called ErbB1 or human epidermal growth factor receptor (HER) 1], ErbB2 (Neu or HER2), ErbB3 (HER3) and ErbB4 (HER4) [2] . Pituitary expression of the more comprehensively studied receptors and ligands in the ErbB family is presented in Table 1 and has been comprehensively reviewed by Cooper et al. [2] . Although EGFR and HER2 are the most well studied, ErbB3 expression has also been demonstrated in prolactinomas and increased expression was noted in a prolactin (PRL)-secreting carcinoma [3] , and ErbB4 expression has been noted in corticotroph adenomas [4] .
To date, three EGFR tyrosine kinase inhibitors (TKIs), gefitinib, lapatinib and canertinib, have been evaluated in the treatment of pituitary tumours. Gefitinib binds the EGFR ATP-binding site, selectively inhibiting EGFR activity, while lapatinib binds the ATP-binding pocket of the EGFR/HER2 protein kinase domain and prevents their
TARGETING THE ErbB PATHWAY IN CORTICOTROPH ADENOMAS
Although all of the ErbB pathway receptors are expressed in corticotrophs, EGFR is far more common and is expressed in 75% of human corticotroph tumours (reviewed in [2] ). Treatment of human primary pituitary corticotroph tumour cultures with gefitinib dose-dependently reduced proopiomelanocortin (POMC) mRNA by 95% [6] , underscoring its potential value as a therapeutic target. Reduction of both POMC mRNA and ACTH was also observed in the culture medium of gefitinib-treated canine primary pituitary corticotroph tumour cultures. When AtT20 mouse corticotroph tumour cells were transfected to overexpress EGFR, activation of both extracellular signal-regulated kinase (ERK) and Akt pathways was observed and increased cell proliferation was evident, all of which were inhibited by gefitinib treatment. In addition, features of hypercortisolemia in mice harbouring xenografts of EGFR-transfected AtT20 cells were reversed by gefitinib treatment [6] .
The recent discovery of gain-of-function mutations in ubiquitin-specific protease 8 (USP8) provided the first molecular mechanism to explain the aberrant EGFR signalling in corticotrophs [7,8 && ,9] . Upon ligand binding, variable lysine residues on EGFR are either mono or poly-ubiquitinated, promoting EGFR trafficking to degradation [10] . USP8 is a deubiquitinase that catalyzes removal of a ubiquitin residue from EGFR, thereby protecting EGFR from trafficking to the lysosome for degradation [11] . In humans, 14-3-3 proteins bind UPS8 at phosphorylated Ser718, which resides in the 14-3-3 binding motif RSYpSSP located at amino acids 715-720, and catalytically repress USP8 deubiquitination activity [12] .
In an elegant and comprehensive analysis of corticotroph adenoma, Reincke et al. [8 && ] demonstrated that heterozygous somatic USP8 single nucleotide mutation or deletions at or adjacent to the 14-3-3 protein binding domain make USP8 resistant to 14-3-3 protein binding and more prone to proteolytic cleavage, which, in turn, leads to higher rate of USP8-induced EGFR deubiquitination activity upon binding of EGF to its receptor. Levels of deubiquitinated EGFR recycled to the cell membrane as well as its membrane expression were shown to increase in cells harbouring USP8 mutations. Moreover, in USP8 mutant-harbouring cells, EGF binding stimulated ERK1/2 phosphorylation to a greater extent than in cells harbouring wild-type USP8, resulting in increased Pomc promoter activity and ACTH synthesis [8 && ]. USP8 mutations were present in six of 17 corticotroph adenomas analysed (35%), while no mutation was observed in other tumour subtypes (two ACTHsecreting Nelson's syndrome tumours, 14 growth hormone secreting adenomas, 10 prolactinomas or 10 nonfunctioning pituitary adenomas). Patients harbouring the mutations were female, had smaller adenomas, lower plasma ACTH levels and had lower serum cortisol after 1 mg dexamethasone suppression test than did patients with Cushing disease not harbouring USP8 mutations [ TKI therapy targeting ErbB receptors shows preliminary efficacy in dopamine agonist resistant prolactinomas and remains to be validated. Normal pituitary
EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; NA, no data available; TGF, transforming growth factor; þ, present; þþ, highly expressed; À, absent. Based on data from [2] .
Cushing disease with USP8 mutations. Among 60 tumours studied, patients with mutated tumours were all female, and showed lower ACTH levels, smaller tumour size and a higher likelihood of surgical remission than wild-type tumours. POMC mRNA expression was higher in mutated tumours and positively correlated with USP8 mRNA expression. However, EGFR mRNA and protein expression did not differ between wild-type and mutant tumours, although EGFR protein expression was higher in those with aggressive Crooke's cell adenomas [13 & ]. Perez-Rivas et al. [9] extended the analysis to 134 Cushing disease adenomas and 11 silent corticotroph adenomas. Forty-eight of the 134 (35.8%) adenomas from patients with Cushing disease had USP8 mutations versus none of the tumours from patients with silent corticotroph adenoma [9] . USP8-Ser718 and USP8-Pro720 were mutated in 52% and 48% of mutation-positive adenomas, respectively. USP8 mutation was more prevalent in women and adults and was associated with less postoperative adrenal insufficiency. There was no difference in baseline plasma ACTH levels or serum cortisol levels after dexamethasone suppression test between patients harbouring the mutant USP8 versus the wild-type USP8. Of note, when microadenomas were analysed separately, USP8 mutantharbouring adenomas were smaller than those with wild-type USP8 [9] .
Finally, Ma et al. [7] showed 17 somatic USP8 mutations in ACTH-secreting pituitary adenomas from 67 of 108 (62%) Chinese patients; 77.6% of these mutations were at Ser718 and Pro720. Immunohistochemistry showed higher EGFR expression in half and more intense ERK1/2 phosphorylation in 80% of USP8-mutated tumours examined versus tumours harbouring wild-type USP8. POMC mRNA levels were also higher in USP8-mutated tumours. When overexpressed in HeLa cells, USP8 mutations were associated with reduced EGFR ubiquitination and degradation as compared with wild-type controls. USP8 knockdown as well as treatment with gefitinib reduced ACTH secretion in primary cultures of USP8-mutated ACTH-secreting pituitary tumours [7] .
Predominant nuclear localization of EGFR was shown in human and canine corticotroph tumours [6] , as was UPS8 in USP8-mutated human corticotroph tumours [8 && ]. By contrast, nonmutated corticotroph expressed UPS8 in both cytoplasm and nucleus in humans [8 && ] and canines [14] . This suggests further association of the two molecules, and awaits further elucidation.
Although a USP8 inhibitor is readily available [15] , none of the above studies utilized it in an attempt to suppress mutated USP8 activity. In mouse AtT20 pituitary corticotroph cells, a USP8 inhibitor (9-ehtyloxyimino9H-indeno [1,2-b] pyrazine-2,3-dicarbonitrile) downregulated EGFR protein expression, attenuated ACTH synthesis and promoted cell apoptosis [16] . However, it is as yet unknown whether USP8 is mutated in AtT20 cells and whether the increased deubiquitination activity of mutated USP8 can be inhibited by a USP8 inhibitor.
Studies on the role of ErbB4 in corticotroph adenomas are also underway [4] . In 14 cultured human corticotroph adenomas, ErbB4 was detected in all tumours, and canertinib, an experimental pan-ErbB receptor TKI dose-dependently suppressed POMC mRNA and ACTH secretion, with a 70% reduction seen in those with higher ErbB expression and no response in those with low levels. Tumours with high ErbB4 expression also tended to be smaller and less invasive. These data suggest a potential role for inhibitors that target multiple ErbB receptors simultaneously.
TARGETING THE ErbB PATHWAY IN LACTOTROPH ADENOMAS
The effect of ErbB pathway signalling on lactotroph tumorigenesis was demonstrated following expression of EGFR or HER2 in the pituitaries of mice using rat PRL enhancer and promoter [17] . Enlarged pituitaries or pituitary adenomas were observed in 30% of female EGFR transgenic mice versus 8% of wildtype mice at ages 11-13 months, while 41% of female HER2 transgenic mice exhibited enlarged pituitaries or pituitary adenomas versus 8% in wild-type mice. Both transgenic mouse models had a four to five-fold increase in circulating PRL levels, which was reduced by 60% in EGFR transgenic mice and by 40% in HER2 transgenic mice after treatment with lapatinib. Treatment with lapatinib did not affect circulating PRL levels in control mice. Western blot analysis of pituitary tissue demonstrated inhibition of PRL expression as well as ERK and Akt phosphorylation with lapatinib in transgenic mice but not in control mice [17] .
Gene expression data confirmed that EGF and EGFR are aberrantly expressed in prolactinomas [18] , and over half of prolactinomas express EGFR and 26% express HER2 (reviewed in [2] ). More aggressive pituitary adenomas show higher EGFR and HER2 protein expression, with 40% of invasive adenomas staining positive for HER2 compared with 1.2% of noninvasive adenomas [19] . We demonstrated that approximately 80% of 28 human prolactinomas express ErbB receptors [20] , with EGFR positivity in 23 out of 28 (82%), HER2 positivity in 24 out of 26 (92%), ErbB3 positivity in seven out of 28 (25%) and ErbB4 positivity in 20 out of 28 (71%). Higher ErbB3 expression correlated with higher rates of optic chiasm compression, suprasellar extension and encasement of the carotids. Higher ErbB4 was observed in tumours with sphenoid sinus invasion than in those without invasion. Two individuals who experienced tumour shrinkage and PRL reduction on dopamine agonist therapy had tumours that stained 100% positive for ErbB3 on their adenomas compared with 13 without tumour reduction who had 0-10% ErbB3 staining [20] .
HER2 was further shown to have a significant role in prolactinomas, as treatment with the dual TKI lapatinib decreased PRL by 90% compared with minimal response to gefitinib in primary culture of human prolactinomas [21] . Following on these data, we initiated a 6-month proof-of-concept clinical trial with lapatinib in patients with dopamine agonist resistant prolactinomas. The first individual presented with continued growth of her prolactinoma (4 cm at the time of study) and PRL elevation despite 13 years of cabergoline 7 mg/week and surgery. With the addition of lapatinib, she demonstrated near normalization of PRL and a 22% reduction in tumour volume (Fig. 1) . The second individual similarly had persistent hyperprolactinemia and tumour growth on cabergoline 7 mg/week for 4 years and after surgery; with the addition of lapatinib, she achieved a 42% reduction in PRL and tumoral size stabilization [20] . These encouraging responses to lapatinib in patients with prolactinomas are now being validated in an ongoing multisite Phase IIa trial in patients with resistant prolactinomas.
CONCLUSION
ErbB pathway is overexpressed in pituitary corticotroph and lactotroph adenomas, and preclinical models demonstrate that functional regulation of tumoral growth and hormonal secretion respond to EGFR TKI therapy. Although there is a suggestion that EGFR expression correlates with more (c) Graph shows PRL levels (ng/ml) and tumour volumes (ml) at baseline (study visit 1) and at monthly intervals. Modified from [20] .
aggressive behaviour in lactotroph tumours, it remains to be seen whether targeting this pathway will open an avenue of new therapy. The discovery of UPS8 mutations that increase EGFR activity in corticotroph tumours supports a role for EGFRtargeting therapeutics in patients with Cushing disease, but this approach has yet to be tested. In prolactinomas, only preliminary evidence is available of possible efficacy of a TKI in resistant tumours. Therefore, we need to await results of clinical trials before recommending TKI therapy for patients with prolactinomas.
Nevertheless, as with the increasing role of TKIs in metastatic thyroid cancer, therapies aimed at specific molecular targets are coming to the forefront of pituitary tumour management. This molecularly targeted approach has the potential to reduce morbidity and cost of unnecessary interventions, ensuring that the patients receive the appropriate therapy and potentially changing the treatment algorithm in the medical management of aggressive pituitary adenomas.
